240 related articles for article (PubMed ID: 26334096)
21. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
[TBL] [Abstract][Full Text] [Related]
23. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
[TBL] [Abstract][Full Text] [Related]
24. Role of gemcitabine in ovarian cancer treatment.
Lorusso D; Di Stefano A; Fanfani F; Scambia G
Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P; Buck M; Beale P; Goldrick A; Allan S; Fitzharris B; De Souza P; Links M; Kalimi G; Davies T; Stuart-Harris R
Int J Gynecol Cancer; 2007; 17(2):359-66. PubMed ID: 17362313
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
Galligioni E; Arcuri C; Sorio R; Griso C
Ann Oncol; 2006 May; 17 Suppl 5():v195-8. PubMed ID: 16807455
[TBL] [Abstract][Full Text] [Related]
27. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
[TBL] [Abstract][Full Text] [Related]
28. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
29. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.
Rahma OE; Ashtar E; Czystowska M; Szajnik ME; Wieckowski E; Bernstein S; Herrin VE; Shams MA; Steinberg SM; Merino M; Gooding W; Visus C; Deleo AB; Wolf JK; Bell JG; Berzofsky JA; Whiteside TL; Khleif SN
Cancer Immunol Immunother; 2012 Mar; 61(3):373-84. PubMed ID: 21927947
[TBL] [Abstract][Full Text] [Related]
30. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Hong SH; Lee S; Kim HG; Lee HJ; Jung KH; Lee SC; Lee NR; Yun J; Woo IS; Park KH; Kim KH; Kim HY; Rha SY; Byun JH
Gynecol Oncol; 2015 Feb; 136(2):212-7. PubMed ID: 25462205
[TBL] [Abstract][Full Text] [Related]
32. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Ledermann JA; Gabra H; Jayson GC; Spanswick VJ; Rustin GJ; Jitlal M; James LE; Hartley JA
Clin Cancer Res; 2010 Oct; 16(19):4899-905. PubMed ID: 20719935
[TBL] [Abstract][Full Text] [Related]
34. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Greggi S; Salerno MG; D'Agostino G; Ferrandina G; Lorusso D; Manzione L; Mancuso S; Scambia G
Oncology; 2001; 60(1):19-23. PubMed ID: 11150903
[TBL] [Abstract][Full Text] [Related]
35. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
[TBL] [Abstract][Full Text] [Related]
36. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
37. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract][Full Text] [Related]
38. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Lund B; Hansen OP; Theilade K; Hansen M; Neijt JP
J Natl Cancer Inst; 1994 Oct; 86(20):1530-3. PubMed ID: 7932808
[TBL] [Abstract][Full Text] [Related]
40. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.
Gasent Blesa JM; Alberola Candel V; Provencio Pulla M; Esteban González E; Martín Algarra S
Clin Transl Oncol; 2009 Jan; 11(1):35-40. PubMed ID: 19155202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
